Incyte Balance Sheet Health
Financial Health criteria checks 6/6
Incyte has a total shareholder equity of $3.7B and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $5.7B and $2.1B respectively. Incyte's EBIT is $209.7M making its interest coverage ratio -2. It has cash and short-term investments of $2.4B.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | -2x |
| Cash | US$2.41b |
| Equity | US$3.67b |
| Total liabilities | US$2.08b |
| Total assets | US$5.75b |
Recent financial health updates
No updates
Recent updates
Investors Aren't Buying Incyte Corporation's (NASDAQ:INCY) Revenues
Apr 30
Incyte: Still A 'Buy' Despite HS Treatment Data With Povorcitinib
Mar 18Incyte: Q4 Earnings Outlines Multiple Drug Launches In 2025
Feb 11Incyte: Multiple Drug Launches Bode Well For Future Growth
Jan 11Incyte: Q3 Earnings Ramping Up Growth To Jump The Patent Cliff
Oct 31
Tactical Expansions And First-in-Class Molecules Set To Propel Growth In High-Need Medical Areas
Incyte's focus on expanding its clinical pipeline with first-in-class molecules and novel therapies aims to drive growth by increasing market share and revenue.Incyte: Monjuvi Advancement Continues With Positive FL Treatment Data
Aug 19Incyte: The Worst Has Been Avoided
Jun 16Incyte Pharmaceuticals: Cheap Enough Now (Rating Upgrade)
Apr 26Incyte: A Potential GARP Superstar
Feb 27Financial Position Analysis
Short Term Liabilities: INCY's short term assets ($3.5B) exceed its short term liabilities ($1.7B).
Long Term Liabilities: INCY's short term assets ($3.5B) exceed its long term liabilities ($361.5M).
Debt to Equity History and Analysis
Debt Level: INCY is debt free.
Reducing Debt: INCY has no debt compared to 5 years ago when its debt to equity ratio was 1%.
Debt Coverage: INCY has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: INCY has no debt, therefore coverage of interest payments is not a concern.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/06/18 04:04 |
| End of Day Share Price | 2025/06/18 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Incyte Corporation is covered by 53 analysts. 23 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jasper Hellweg | Argus Research Company |
| Thomas Russo | Baird |
| Ishan Majumdar | Baptista Research |